论文部分内容阅读
丁螺旋酮是一种非镇静、非苯二氮(艹卓)类的抗焦虑药,作者比较了该药与安慰剂治疗经前期综合征(PMS)患者的疗效。2个周期安慰剂治疗后,患者在月经周期的最后12天以双盲,随机方式分别服用日均量25mg 的丁螺旋酮(17人)或安慰剂(17人),共连续3个月经周期。患者平均年龄31岁,均达到 PMS 标准,经后几乎无疵状,经前有中至重度症状。严重抑郁症者除外。最终测定是病人完成17条日记录,包括急躁、抑郁、肿胀、痛性痉挛、食物瘾等,每条每日按0(无症状)至4(症状严重)级来评价。鉴于丁螺旋酮作用缓慢,作者选择月经周期的第26～28天的日记得分作为经前期痛苦的标志,第8～10天的得分作为经后症状的标志。结果:与安慰剂相比,丁螺旋酮降低 PMS 症状显著(P<0.03)。总的17条中,丁螺旋酮对下列几条的疗效明显:酸痛(P<0.01)、疲劳(P<0.05)、痛性痉挛(P<0.05),社交力受损(P<0.05)和应激性(P<0.10)等。这些结果符合血清素激活剂在 PMS中起作用的假设,如果本文结果得到证实,丁螺旋
Buspirone is a non-sedating, non-benzodiazepine anti-anxiety drug. The authors compared the efficacy of this drug with placebo in the treatment of patients with premenstrual syndrome (PMS). After 2 cycles of placebo treatment, patients were treated with either buspirone (17) or placebo (17) in an average daily dose of 25 mg in a double-blind, randomized fashion for the last 12 days of the menstrual cycle for a total of 3 menstrual cycles . The average age of patients was 31 years old, both reached PMS standards, almost no defect after the passage of the former have moderate to severe symptoms. Except for severe depression. The final determination was that the patient completed 17 daily records, including impatience, depression, swelling, cramps, food addiction, etc., each rated as 0 (asymptomatic) to 4 (severe) daily. In view of the slow action of bupivirone, the author chose the diary score of the 26th to 28th days of the menstrual cycle as a marker of premenstrual pain and the score of 8th to 10th days as a marker of postmenstrual symptoms. Results: Butpirone reduced PMS symptoms significantly (P <0.03) compared with placebo. In the total of 17, the efficacy of buspirone on the following was obvious: pain (P <0.01), fatigue (P <0.05), painful cramps (P <0.05) Stress (P <0.10) and so on. These results are consistent with the hypothesis that serotonin activators play a role in PMS. If the results of this article are validated,